transient dynam hamper top-lin expect improv
share like lag clearer pictur emerg pt
maintain buy rate lower pt
follow result report result saw revenue
xfx miss btig/consensu estimate
ep beat estim revenu choppi delay
purchas ahead npi domest erp transit issu time dynam
combin pressur top-lin across multipl segment dynam off-set
expens control op leverag limit sg financi leverag drove
gain guidanc call organ growth ep
exclud impact ncov organ growth expect acceler
one-tim event cloud overal pictur feel headwind
 mostli transitori specif expect concern abound key
product segment tavr diabet see slower growth
modestli delay timelin management would commit acceler
organ growth suggest would acceler impli
xfx growth continu full pipelin offer
improv organ growth acceler line omx bp remain
place lead ep floor outer year lower pt
cloud pictur near-term continu see valu pipelin enhanc
top-lin perform yield improv leverag increas ep time
pipelin remain intact note slight chang diabet time management
call recent us approv micra av fistula indic admir av
mazor stealth cranial robot system well european approv
cobalt chrome high power devic interstim micro sacral neuromodul
devic percept futur product note includ us approv cobalt
chrome interstim micro dtm percept pcdb well european
approv minim diamond temp ablat cathet
management expect data minim submit fda march
push back us approv least earliest
oper shift sale forc may present near-term choppi
management note mani mdt order across segment come last month
 present plan risk result top-lin miss
management confid abil drive chang toward uniform
order involv chang sale forc incent
oper structur around sell process management intend discuss
propos plan commun specif sale forc
busi ultim less volatil impli today result
believ present slight disrupt risk near-term
china/ncov impact china make mdt revenu mdt factori
china run management suggest limit suppli exposur china
abl identifi factori produc hemodialysi diabet
product chengdu hubei provinc well orthoped product
beij changzhou jiangsu provinc like concern
suppli side numer third-parti manufactur like use
valuat rate buy pt base mo
ep estim risk discuss
idc btig estim compani document
million except per share amount
medtron rate buy believ qualiti pipelin launch nearli everi product segment posit
compani well improv growth start back half meanwhil introduct robot platform
provid increment revenu stream final compani strong track record free cash flow gener offer
consider cushion earn growth
base case assum perform within mdt current guidanc call
top-lin constant currenc growth non-gaap ep
upsid base case would come higher organ growth new
product introduct regulatori clearanc faster assum loss
competit key area better expect om expans
one largest
diversifi compani
med-tech sell product
cardiac vascular group
restor therapi diabet
downsid base case would result slower product growth
competit encroach key market segment slower regulatori approv
impact higher expect competit global macroeconom
challeng slow global growth
report result consolid revenu xfx behind btig consensu
estim call us revenu ou revenu
xfx compar btig/consensu estim
overal organ growth came
segment cvg report revenu xfx came btig consensu estim
within cvg report cardiac rhythm heart failur coronari structur
heart aortic peripher vascular revenu xfx xfx
xfx compar btig/consensu estim
mitg report revenu xfx btig consensu estim y/i
y/i surgic innov respiratori gi renal revenu came xfx
xfx compar btig/consensu estim
rtg report revenu xfx in-lin btig consensu estim
respect spine brain specialti pain revenu came xfx
xfx xfx xfx compar btig/consensu
estim y/i y/i
y/i y/i
diabet revenu came flat xfx compar btig consensu estim y/i
adj gross margin bp stronger estim sg margin came
bp higher bp lower estim respect overal adj oper margin
bp stronger estim interest expens estim adj tax rate
bp estim told adj ep came btig/consensu estim
made follow chang model
within revenu tweak expect fall closer management guidanc organ revenu
growth within cvg model slightli higher crhf revenu beyond improv contribut new
product coronari structur heart remain unchang us aortic peripher expect fall slightli
previous assum growth rate land xfx growth cvg mitg model xfx growth
in-lin management guidanc growth rate lower previous assum mitg recov lost
procedur due erp implement impact rtg model xfx meaning
lower previou expect rtg chang rtg driven weaker anticip growth spine
pain therapi within diabet model declin xfx diabet commerci timelin competit
pressur continu impact result higher anticip
 adjust slightli beyond tweak oper expens fall in-lin management
guidanc note essenti flat om y/i ultim omx tweak interest
expens tax slightli well ultim expect grow ep
actualsbtig estimate varianceww cardiac rhythm hf cardiac vascular group minim spine restor therapi diabet net bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani filingsvari
medtron rate buy pt previous base share trade month ep
estim target multipl similar current multipl ntm earn believ qualiti pipelin launch
nearli everi product segment posit compani well acceler revenu growth note result
hamper mdt momentum near-term guidanc establish expect achiev
meanwhil introduct robot platform offer increment revenu stream final compani
strong track record free cash flow gener offer consider cushion earn growth risk includ
deterior cardiac market delay robot launch advers tax propos soft emerg market margin
degrad expans new busi line competit slippag product timelin chang procedur
reimburs futur devic data fda use cash/m tariff possibl multipl contract
bpsc growth bpsadj net bpsgross bpsebit bpssourc btig estim compani filingsnewold chang
medtron incom eproduct net y/i good gross total oper oper expens adj oper interest expens non-oper expense/ inc pre-tax incom adj net non-controlling adj net incom adjust ep share total net oper net product product product oper btig estim compani report
medtron revenu model ecrm heart failur structur heart y/i peripher vascular total recast y/i vascular group y/i patient monitor recoveri y/i invas therapi group y/i recast therapi recast therapi recast therapi recast therapi group y/i group y/i y/i oper y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
